Revvity, Inc. (NYSE:RVTY) Shares Acquired by Natixis Advisors LLC

Natixis Advisors LLC increased its position in shares of Revvity, Inc. (NYSE:RVTY) by 17.9% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,499 shares of the company’s stock after acquiring an additional 1,901 shares during the period. Natixis Advisors LLC’s holdings in Revvity were worth $1,597,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. EdgePoint Investment Group Inc. acquired a new stake in shares of Revvity during the second quarter worth about $209,221,000. Dimensional Fund Advisors LP grew its stake in shares of Revvity by 5.3% in the second quarter. Dimensional Fund Advisors LP now owns 1,149,122 shares of the company’s stock worth $120,506,000 after acquiring an additional 57,656 shares in the last quarter. Ceredex Value Advisors LLC increased its position in shares of Revvity by 2.2% during the second quarter. Ceredex Value Advisors LLC now owns 1,094,938 shares of the company’s stock worth $114,815,000 after acquiring an additional 23,318 shares during the period. RGM Capital LLC increased its position in shares of Revvity by 6.7% during the second quarter. RGM Capital LLC now owns 950,858 shares of the company’s stock worth $99,707,000 after acquiring an additional 59,994 shares during the period. Finally, The Manufacturers Life Insurance Company raised its stake in shares of Revvity by 5.6% in the second quarter. The Manufacturers Life Insurance Company now owns 551,880 shares of the company’s stock valued at $57,870,000 after acquiring an additional 29,204 shares in the last quarter. 86.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Revvity

In other Revvity news, insider Tajinder S. Vohra sold 2,154 shares of the business’s stock in a transaction on Wednesday, October 9th. The shares were sold at an average price of $121.73, for a total value of $262,206.42. Following the transaction, the insider now directly owns 19,652 shares of the company’s stock, valued at approximately $2,392,237.96. The trade was a 9.88 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.60% of the stock is owned by company insiders.

Revvity Price Performance

RVTY stock opened at $114.66 on Tuesday. The company has a current ratio of 3.56, a quick ratio of 2.97 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $13.95 billion, a P/E ratio of 55.39, a PEG ratio of 2.80 and a beta of 1.05. The business has a 50 day simple moving average of $120.37 and a 200-day simple moving average of $115.81. Revvity, Inc. has a twelve month low of $86.30 and a twelve month high of $129.50.

Revvity (NYSE:RVTY) last issued its quarterly earnings results on Monday, November 4th. The company reported $1.28 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.15. The firm had revenue of $684.10 million during the quarter, compared to analysts’ expectations of $679.66 million. Revvity had a net margin of 9.34% and a return on equity of 7.42%. Revvity’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.18 EPS. As a group, equities analysts anticipate that Revvity, Inc. will post 4.85 EPS for the current year.

Revvity announced that its Board of Directors has authorized a stock buyback plan on Monday, November 4th that permits the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization permits the company to buy up to 6.5% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Revvity Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 7th. Shareholders of record on Friday, January 17th will be paid a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.24%. The ex-dividend date of this dividend is Friday, January 17th. Revvity’s dividend payout ratio is presently 13.53%.

Analyst Ratings Changes

A number of equities research analysts have issued reports on RVTY shares. Leerink Partners increased their price target on Revvity from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Barclays lowered their price target on shares of Revvity from $140.00 to $135.00 and set an “overweight” rating for the company in a report on Monday. Bank of America raised their price objective on shares of Revvity from $118.00 to $127.00 and gave the company a “neutral” rating in a report on Tuesday, July 30th. Jefferies Financial Group boosted their target price on shares of Revvity from $115.00 to $125.00 and gave the stock a “hold” rating in a research note on Monday, July 29th. Finally, Raymond James raised their price target on Revvity from $144.00 to $146.00 and gave the company an “outperform” rating in a research note on Tuesday, November 5th. Seven equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $131.73.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.